Clinical trials referenced in this document:
Documents that mention this clinical trial
30-days effects of vildagliptin on vascular function, plasma viscosity, inflammation, oxidative stress, and intestinal peptides on drug-naïve women with diabetes and obesity: a randomized head-to-head metformin-controlled study
Funding for this research was provided by:
Novartis S.A. (CLAF237ABR04T)
Received: 19 May 2019
Accepted: 16 August 2019
First Online: 23 August 2019
Ethics approval and consent to participate
: The protocol was approved by the local Research Ethical Committee (COEP: 0.87.3.2012) and carried out by the principles of the Declaration of Helsinki. All subjects gave written informed consent.
: All authors approve this study for publication in Diabetology & Metabolic Syndrome.
: The authors declare that they have no competing interests. LGK-A received funds from Novartis S.A. that partially supported this study.